Literature DB >> 4034883

Implantable narcotic antagonists: a possible new treatment for narcotic addiction.

C N Chiang, A Kishimoto, G Barnett, L E Hollister.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4034883

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN： 0048-5764


× No keyword cloud information.
  6 in total

1.  Plasma concentrations during naltrexone implant treatment of opiate-dependent patients.

Authors:  Linda Olsen; Asbjørg S Christophersen; Grete Frogopsahl; Helge Waal; Jørg Mørland
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

2.  Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin.

Authors:  Maria A Sullivan; Suzanne K Vosburg; Sandra D Comer
Journal:  Psychopharmacology (Berl)       Date:  2006-09-14       Impact factor: 4.530

3.  Depot naltrexone: long-lasting antagonism of the effects of heroin in humans.

Authors:  Sandra D Comer; Eric D Collins; Herbert D Kleber; Elie S Nuwayser; James H Kerrigan; Marian W Fischman
Journal:  Psychopharmacology (Berl)       Date:  2001-11-01       Impact factor: 4.530

4.  Studies on in vitro availability, degradation, and thermal properties of naltrexone-loaded biodegradable microspheres.

Authors:  Emmamuel O Akala; Pornruedee Wiriyacoonkasem; Gaofeng Pan
Journal:  Drug Dev Ind Pharm       Date:  2011-03-30       Impact factor: 3.225

5.  Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.

Authors:  Sandra D Comer; Maria A Sullivan; Elmer Yu; Jami L Rothenberg; Herbert D Kleber; Kyle Kampman; Charles Dackis; Charles P O'Brien
Journal:  Arch Gen Psychiatry       Date:  2006-02

6.  Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX).

Authors:  Nikolaj Kunøe; Arild Opheim; Kristin Klemmetsby Solli; Zhanna Gaulen; Kamni Sharma-Haase; Zill-E-Huma Latif; Lars Tanum
Journal:  BMC Pharmacol Toxicol       Date:  2016-04-28       Impact factor: 2.483
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.